British scientists tested the first AI-designed coronavirus vaccine in humans

British scientists conducted the first human trial of a universal coronavirus vaccine designed with artificial intelligence. The vaccine proved safe, but its protective efficacy was difficult to assess because some participants contracted the disease before completing the full vaccination course.

UK scientists tested an AI-designed universal coronavirus vaccine in humans for the first time, marking a significant step forward in both artificial intelligence applications and vaccine technology development.

According to the results of the clinical trial, the AI-designed vaccine proved safe and did not cause serious adverse effects in participants. This is an important prerequisite for further development of the vaccine in the future.

However, assessment of the vaccine's protective efficacy remained challenging. Several trial participants contracted coronavirus disease before they had completed the full vaccination course, while others received a conventional COVID-19 vaccine in the interim. This complicated the direct measurement of protective efficacy.

The scientists' goal is to create a universal vaccine that would provide broad protection against different coronavirus variants. Using artificial intelligence in vaccine design opens new possibilities, as AI can rapidly analyse large datasets and predict which protein structures could most effectively trigger an immune response.